OBJECTIVES: In England, national guidance recommends that all patients with suspected invasive meningococcal disease (IMD) should be investigated by blood culture and polymerase chain reaction (PCR) testing. The Meningococcal Reference Unit (MRU) provides a national service for meningococcal species confirmation and PCR-testing of clinical samples. We performed a population-level assessment of the added value of PCR-testing for IMD to augment traditional culture confirmation. METHODS: We analysed all PCR-samples and invasive meningococcal isolates received by MRU in 2009 and 2010. We assumed that all patients with PCR-samples submitted to MRU also had blood cultures performed and that positive blood cultures were referred to MRU. We confirmed this assertion by case ascertainment. RESULTS: In total, 25,379 specimens from 22,039 patients were submitted for PCR-testing and 1492 (6.8%) tested PCR-positive. MRU received 825 invasive meningococcal isolates; 393 confirmed by PCR and culture, 405 without a PCR-specimen submitted and 27 with a PCR-negative result. Thus, of 1924 reported IMD cases, 1099 (57.1%) were confirmed by PCR only, 432 (22.5%) by culture only and 393 (20.4%) by both tests. CONCLUSION: More than half of all confirmed IMD cases were confirmed by PCR only, indicating this service ensures high case ascertainment for national surveillance.
OBJECTIVES: In England, national guidance recommends that all patients with suspected invasive meningococcal disease (IMD) should be investigated by blood culture and polymerase chain reaction (PCR) testing. The Meningococcal Reference Unit (MRU) provides a national service for meningococcal species confirmation and PCR-testing of clinical samples. We performed a population-level assessment of the added value of PCR-testing for IMD to augment traditional culture confirmation. METHODS: We analysed all PCR-samples and invasive meningococcal isolates received by MRU in 2009 and 2010. We assumed that all patients with PCR-samples submitted to MRU also had blood cultures performed and that positive blood cultures were referred to MRU. We confirmed this assertion by case ascertainment. RESULTS: In total, 25,379 specimens from 22,039 patients were submitted for PCR-testing and 1492 (6.8%) tested PCR-positive. MRU received 825 invasive meningococcal isolates; 393 confirmed by PCR and culture, 405 without a PCR-specimen submitted and 27 with a PCR-negative result. Thus, of 1924 reported IMD cases, 1099 (57.1%) were confirmed by PCR only, 432 (22.5%) by culture only and 393 (20.4%) by both tests. CONCLUSION: More than half of all confirmed IMD cases were confirmed by PCR only, indicating this service ensures high case ascertainment for national surveillance.
Authors: Bianca Törös; Sara T Hedberg; Magnus Unemo; Susanne Jacobsson; Dorothea M C Hill; Per Olcén; Hans Fredlund; Holly B Bratcher; Keith A Jolley; Martin C J Maiden; Paula Mölling Journal: J Clin Microbiol Date: 2015-04-29 Impact factor: 5.948
Authors: Andries J van Tonder; Shilan Mistry; James E Bray; Dorothea M C Hill; Alison J Cody; Chris L Farmer; Keith P Klugman; Anne von Gottberg; Stephen D Bentley; Julian Parkhill; Keith A Jolley; Martin C J Maiden; Angela B Brueggemann Journal: PLoS Comput Biol Date: 2014-08-21 Impact factor: 4.475
Authors: Dorothea M C Hill; Jay Lucidarme; Stephen J Gray; Lynne S Newbold; Roisin Ure; Carina Brehony; Odile B Harrison; James E Bray; Keith A Jolley; Holly B Bratcher; Julian Parkhill; Christoph M Tang; Ray Borrow; Martin C J Maiden Journal: Lancet Infect Dis Date: 2015-10-27 Impact factor: 25.071
Authors: Odile B Harrison; Christoph Schoen; Adam C Retchless; Xin Wang; Keith A Jolley; James E Bray; Martin C J Maiden Journal: Pathog Dis Date: 2017-08-31 Impact factor: 3.166
Authors: Caroline Cayrou; Ayodeji A Akinduko; Evgeny M Mirkes; Jay Lucidarme; Stephen A Clark; Luke R Green; Helen J Cooper; Julie Morrissey; Ray Borrow; Christopher D Bayliss Journal: PLoS One Date: 2018-05-30 Impact factor: 3.240
Authors: Carina Brehony; Charlene M C Rodrigues; Ray Borrow; Andrew Smith; Robert Cunney; E Richard Moxon; Martin C J Maiden Journal: Vaccine Date: 2016-08-09 Impact factor: 3.641